奇正藏药
(002287)
| 流通市值：119.08亿 | | | 总市值：119.34亿 |
| 流通股本：5.29亿 | | | 总股本：5.30亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 365,098,756.48 | 2,045,152,409.09 | 1,246,236,765.94 | 829,806,620.16 |
| 营业收入 | 365,098,756.48 | 2,045,152,409.09 | 1,246,236,765.94 | 829,806,620.16 |
| 二、营业总成本 | 299,888,820.46 | 1,628,674,386.62 | 957,209,847.78 | 591,405,141.62 |
| 营业成本 | 68,028,674.83 | 323,314,878.11 | 194,884,907.21 | 129,594,799.97 |
| 税金及附加 | 5,733,101.07 | 34,839,602.1 | 21,564,277.61 | 14,148,839.01 |
| 销售费用 | 169,679,519.01 | 977,775,312.89 | 533,538,618.18 | 311,214,347.63 |
| 管理费用 | 34,104,822.67 | 183,889,213.93 | 129,660,157.99 | 77,983,567.3 |
| 研发费用 | 12,018,942.57 | 58,626,314.46 | 40,133,818.82 | 27,157,833.09 |
| 财务费用 | 10,323,760.31 | 50,229,065.13 | 37,428,067.97 | 31,305,754.62 |
| 其中:利息费用 | 15,934,238.46 | 63,069,765.65 | 45,803,333.22 | 35,652,800.51 |
| 其中:利息收入 | 5,667,401.37 | 13,137,410.79 | 8,579,430.92 | 4,487,486.03 |
| 加:公允价值变动收益 | 28,119,979.91 | 37,074,168.19 | 29,040,287.15 | 28,048,327.52 |
| 加:投资收益 | 10,285,742.77 | 28,779,857.94 | 44,169,642.94 | 69,099,357.05 |
| 资产处置收益 | - | 318,156.83 | 143,431.27 | 143,431.27 |
| 资产减值损失(新) | - | -1,401,294.38 | 56,284.87 | 56,284.87 |
| 信用减值损失(新) | -62,952.26 | -1,271,636.55 | -3,361,416.6 | -1,732,612.45 |
| 其他收益 | 9,808,790.23 | 166,405,670.53 | 55,767,051.14 | 6,436,227.34 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 113,361,496.67 | 646,382,945.03 | 414,842,198.93 | 340,452,494.14 |
| 加:营业外收入 | 79,713.77 | 317,626.34 | 135,905.96 | 47,913.7 |
| 减:营业外支出 | 148,999.72 | 2,287,701.01 | 1,848,412.12 | 1,664,148.08 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 113,292,210.72 | 644,412,870.36 | 413,129,692.77 | 338,836,259.76 |
| 减:所得税费用 | 14,598,032.27 | 65,235,125.72 | 33,588,171.96 | 28,136,057.17 |
| 六、净利润 | 98,694,178.45 | 579,177,744.64 | 379,541,520.81 | 310,700,202.59 |
| 持续经营净利润 | 98,694,178.45 | 579,177,744.64 | 379,541,520.81 | 310,700,202.59 |
| 归属于母公司股东的净利润 | 97,460,837.34 | 581,198,850.19 | 380,504,760.77 | 312,267,146.68 |
| 少数股东损益 | 1,233,341.11 | -2,021,105.55 | -963,239.96 | -1,566,944.09 |
| (一)基本每股收益 | 0.18 | 1.1 | 0.72 | 0.59 |
| (二)稀释每股收益 | 0.18 | 1.1 | 0.72 | 0.59 |
| 八、其他综合收益 | 63,746.45 | 614,638.01 | 1,120,488.97 | 1,355,560.08 |
| 归属于母公司股东的其他综合收益 | 63,746.45 | 614,638.01 | 1,120,488.97 | 1,355,560.08 |
| 九、综合收益总额 | 98,757,924.9 | 579,792,382.65 | 380,662,009.78 | 312,055,762.67 |
| 归属于母公司股东的综合收益总额 | 97,524,583.79 | 581,813,488.2 | 381,625,249.74 | 313,622,706.76 |
| 归属于少数股东的综合收益总额 | 1,233,341.11 | -2,021,105.55 | -963,239.96 | -1,566,944.09 |
| 公告日期 | 2024-04-27 | 2024-04-19 | 2023-10-27 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |